Radiology Doctors in Medford, MA Accepting Medicare

5 Radiology doctors found. Showing 1 - 5

Jeff Velez, M.D. Radiology - Diagnostic Radiology Medicare: Accepting Medicare Assignments Practice Location: 64 Buzzells Ln, Medford, MA 02155 Phone: 617-447-4406

Hugh N Collier, M.D. Radiology - Diagnostic Radiology Medicare: Not Enrolled in Medicare Practice Location: Lawrence Mem. Hospital, Dept. Of Radiology, Medford, MA 02158 Phone: 781-306-6801

Ira N Kirschenbaum, M.D. Radiology - Diagnostic Radiology Medicare: Not Enrolled in Medicare Practice Location: 26 City Hall Mall, Medford, MA 02155 Phone: 781-306-5100    Fax: 781-306-5379

James M Coleman, MD Radiology - Diagnostic Radiology Medicare: Not Enrolled in Medicare Practice Location: 170 Governors Ave, Radiology Department, Medford, MA 02155 Phone: 781-306-6800    Fax: 781-306-6472

Todd Christopher Adams, M.D. Radiology - Radiation Oncology Medicare: Accepting Medicare Assignments Practice Location: 128 Washington St, Medford, MA 02155 Phone: 207-939-9583

News Archive

Cannabinoids may be a target for new strategies in cancer treatment

Cannabis-like substances that are produced by the body have both therapeutic and harmful properties, besides their well-known intoxicating effects, and the body's cannabinoid system may be a target for new strategies in cancer treatment.

Mylan Pharmaceuticals signs settlement and license agreements with Wyeth

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into settlement and license agreements with Wyeth, now part of Pfizer, relating to Venlafaxine Hydrochloride (HCl) Extended Release (ER) Capsules, 37.5 mg, 75 mg and 150 mg, the generic version of Wyeth's Effexor XR® Capsules, a treatment for major depressive disorder.

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

Fight for Sight funds research to investigate genetic risk of age-related macular degeneration

Eye research charity Fight for Sight is funding researchers from the University of Manchester to investigate the genetic risk of the UK's leading cause of blindness, age-related macular degeneration.

Revelation of new genes linked to prostate cancer could single out high risk men

The discovery by researchers of at least ten new genes associated with prostate cancer could in future be used to accurately identify high-risk men.

Read more Medical News

› Verified 1 days ago